Abbott Laboratories has continued to demonstrate steady performance in the US medical device market amid market shifts, though its diagnostics segment experienced a modest decline, according to new insights from GlobalData, a leading data and analytics firm.   

In the first half of 2025, Abbott reported strong financial results, with a 14.8 percent year-over-year increase in US medical device sales compared to the same period in 2024. The company saw modest changes in average selling prices (ASPs) and continued growth in key product lines.

While ASPs for some high-volume product lines showed a slight decline compared to H1 2024, Abbott's top revenue-generating products have maintained consistent ASP across 2024 and 2025, indicating that its core offerings remain well-positioned and resilience to difficult economic situations, such as those brought on by developing tariff policies, according to GlobalData.

Thomas Fleming, Medical Analyst at GlobalData, said: “When analyzing Abbott’s highest-volume products, some nuances emerge. Products that ranked highest by volume of sales in 2024 experienced modest increases in ASP, while those leading by volume in 2025 showed no change or a slight decline in ASP. This pattern may reflect changing purchasing strategies among US healthcare facilities, potentially arising due to evolving priorities in public health and cost considerations.”

GlobalData’s latest data indicates continued strong performance across several key product lines, including MitraClip, Ensite X, and Tactiflex. In the US cardiovascular market, Abbott currently holds approximately 18 percent market share, according to GlobalData.

However, not all segments saw growth. Abbott’s US diagnostics have seen a modest decline in year-over-year sales in Q2 2025, specifically in point-of-care and rapid diagnostics.

 “This appears to be linked to reduced demand for COVID-19 testing, which had previously seen high demand. This shift in demand could be responsible for the changes in Abbott’s high-volume sales,” Fleming noted.